In this single-assignment , unblinded study , we treated fifty-six menopausal women with HCV-G1 , 46 % F3-F4 , and previous PEG - / RBV failure ( 7 % null , 41 % non-responder , and 52 % relapser ) with 4 wk lead-in with PEG-IFN2b / RBV followed by PEG-IFN2b / RBV+B oceprevir for 32 wk , with an additional 12 wk of PEG-IFN -- 2b/RBV if patients were HCV-RNA-positive by week 8 .